) Basic research in the Molecular Oncology Program is directed at understanding molecular mechanisms of oncogenesis with a view toward development of more effective cancer therapies. This goal is being achieved through research related to the program?s three focus areas: (1) signal transduction from the cell surface to the nucleus, (2) nuclear transcription factors and regulation of gene expression, and (3) discovery of new drugs to treat cancer based on targeting signal transduction and gene control mechanisms. In addition to providing scientific focus and leadership, the Program Leader?s efforts are directed at stimulation of interdisciplinary and translational studies involving both intra- and inter-programmatic collaborations. The Molecular Oncology Program comprises 21 faculty members, the majority of whom have been recruited in recent years from outside institutions. Research in this program is funded by $4,3 million in annual direct costs, most of which is peer-reviewed, including over $3,2 million from NCI and all other NIH. One program project grant in cancer drug discovery is funded by NCI, representing an intra-programmatic collaborative effort, and another program project in molecular oncology with a strong translational focus, representing an inter-programmatic collaboration, is pending review by NCI. The program members have been highly productive, with significant numbers of joint publications resulting from intra- and inter-programmatic collaborations. This tremendous progress in the Molecular Oncology Program has been greatly facilitated by the Cancer Center?s continuing commitment in terms of new faculty recruitment and development of the research infrastructure, including state-of-the-art core facilities. Plans for the future include additional recruitment of new faculty to further strengthen drug discovery and cancer genetics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-04
Application #
6430477
Study Section
Project Start
1998-02-19
Project End
2006-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
$305,280
Indirect Cost
Name
University of South Florida
Department
Type
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430

Showing the most recent 10 out of 1254 publications